Shilpa Medicare Ltd

Shilpa Medicare Ltd. Amalgamation Approved by NCLT 📋

- NCLT Bangalore approved the amalgamation on February 27, 2026.

- Appointed date for the merger is set as April 1, 2025.

- Shilpa Therapeutics is a wholly owned subsidiary of SML.

- No new shares will be issued as part of the scheme.

- All employees of Shilpa Therapeutics will be absorbed by SML without any break in service.

- Undisputed statutory dues include Rs. 61.17 lakhs for Shilpa Therapeutics and Rs. 3.59 crores for SML.

- MSME dues total Rs. 25.60 lakhs for Shilpa Therapeutics and Rs. 53.13 lakhs for SML.

- The scheme includes clubbing of authorized share capital.

- SML is responsible for paying differential stamp duty fees.

- The order is binding on all shareholders and creditors.

- SML must preserve all records of Shilpa Therapeutics.